GENESIS PHARMACEUTICALS ENTE
WKN: 931506 / ISIN: US37184Q1022Grosse Chance WKN 931506
| eröffnet am: | 04.04.07 09:33 von: | plusquamperfekt |
| neuester Beitrag: | 02.05.10 14:39 von: | _bbb_ |
| Anzahl Beiträge: | 342 | |
| Leser gesamt: | 40139 | |
| davon Heute: | 3 | |
bewertet mit 3 Sternen |
||
|
|
||
29.10.07 19:28
#80
0815ax
...aussitzen & in Gedanken den garantiert zu
erwartenden Gewinn verplanen !
Bin hier LONG investiert - und vondaher mache ich mir über den momentan in Dtl. nicht vorhandenen Handel kaum/keine Gedanken !!
ciao ax
Bin hier LONG investiert - und vondaher mache ich mir über den momentan in Dtl. nicht vorhandenen Handel kaum/keine Gedanken !!
ciao ax
05.11.07 15:43
#82
0815ax
USA eröffnet im GRÜN
...Konsolidierung sollte (hoff) beendet sein ==> auf eine grüne Woche...
ax
ax
06.11.07 07:29
#84
duffyduck
warum läuft die aktien in frankfurt so schlecht?
in übersee wird immer viel mehr gehandelt
06.11.07 18:18
#86
0815ax
INFO 06.11.07 (engl.)
http://www.stockhouse.com/news/news.asp?newsid=6197313&tick=GTEC
Genesis Technology Group Inc. (OTCBB: GTEC) through its wholly-owned subsidiary Laiyang Jiangbo Biotech Technologies Co., Ltd. ("JiangBo"), is engaged in the research, development, manufacture and sale of pharmaceutical products in the PRC. One of the major pharmaceutical companies in the PRC, Genesis offers a full product line of both western medical drugs and Chinese herbal-based medical drugs in tablet, capsule and granule forms. For the year ending June 30, 2007, net sales for Genesis totaled $76.2 million, up approximately 55 percent from $49.2 million in 2006.
With 85.26 million shares outstanding and 546,000 shares declared short as of October 2007, there is no longer a failure to deliver in shares of GTEC.
Genesis Technology Group Inc. (OTCBB: GTEC) through its wholly-owned subsidiary Laiyang Jiangbo Biotech Technologies Co., Ltd. ("JiangBo"), is engaged in the research, development, manufacture and sale of pharmaceutical products in the PRC. One of the major pharmaceutical companies in the PRC, Genesis offers a full product line of both western medical drugs and Chinese herbal-based medical drugs in tablet, capsule and granule forms. For the year ending June 30, 2007, net sales for Genesis totaled $76.2 million, up approximately 55 percent from $49.2 million in 2006.
With 85.26 million shares outstanding and 546,000 shares declared short as of October 2007, there is no longer a failure to deliver in shares of GTEC.
12.11.07 20:52
#87
0815ax
...nach dem Absturz der letzten Tage durch die
(Privatorder) heute endlich mal wieder ein positiver Trend.
...so langsam sollte/muss der Zug auch hier einmal ins rollen kommen...
ax
...so langsam sollte/muss der Zug auch hier einmal ins rollen kommen...
ax
20.11.07 16:10
#88
0815ax
INFO 20.11.07 (engl.)
http://www.stockhouse.com/news/news.asp?newsid=6222993&tick=GTEC
Genesis Pharmaceuticals Enterprises, Inc. (OTCBB: GTEC), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, yesterday announced its financial results for the quarter ended September 30, 2007, the Company's first quarter of Fiscal Year 2008.
Revenues and profits declined slightly due to a scheduled facility maintenance project that resulted in a manufacturing stoppage for five weeks during the quarter. Adjusting for the impact of the stoppage, revenues would have grown approximately 15% as compared to the same period last year. First quarter revenue was $16.6 million, down 7.7% from Q1 FY 2007 -- Gross profit totaled $12.0 million, down 7.0% from Q1 FY 2007 -- Net income was $3.2 million, down 7.6% from Q1 FY 2007
"Our revenues declined slightly in the first quarter of Fiscal Year 2008 due to a previously scheduled maintenance project implemented by management according to Chinese drug production industry standards. This was the biggest facility maintenance project undertaken by us during the last three years, and critical for maintaining product quality and improving the productivity of our entire production facility. We are pleased to report that the maintenance project was successfully completed, and we achieved record revenues of approximately $8 million in the month of October," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals.
"We are very pleased to have completed our transition to become a public company in the U.S. and believe that Fiscal Year 2008 will be a very exciting and successful year for our company. In addition to the recently launched Baobole chewable tablets we have four other very promising drugs that are awaiting final SFDA approval. We estimate that Fiscal Year 2008 revenues will exceed $100 million and operating income will exceed $26 million," stated Mr. Cao.
Genesis Pharmaceuticals Enterprises, Inc. (OTCBB: GTEC), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, yesterday announced its financial results for the quarter ended September 30, 2007, the Company's first quarter of Fiscal Year 2008.
Revenues and profits declined slightly due to a scheduled facility maintenance project that resulted in a manufacturing stoppage for five weeks during the quarter. Adjusting for the impact of the stoppage, revenues would have grown approximately 15% as compared to the same period last year. First quarter revenue was $16.6 million, down 7.7% from Q1 FY 2007 -- Gross profit totaled $12.0 million, down 7.0% from Q1 FY 2007 -- Net income was $3.2 million, down 7.6% from Q1 FY 2007
"Our revenues declined slightly in the first quarter of Fiscal Year 2008 due to a previously scheduled maintenance project implemented by management according to Chinese drug production industry standards. This was the biggest facility maintenance project undertaken by us during the last three years, and critical for maintaining product quality and improving the productivity of our entire production facility. We are pleased to report that the maintenance project was successfully completed, and we achieved record revenues of approximately $8 million in the month of October," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals.
"We are very pleased to have completed our transition to become a public company in the U.S. and believe that Fiscal Year 2008 will be a very exciting and successful year for our company. In addition to the recently launched Baobole chewable tablets we have four other very promising drugs that are awaiting final SFDA approval. We estimate that Fiscal Year 2008 revenues will exceed $100 million and operating income will exceed $26 million," stated Mr. Cao.
20.11.07 19:44
#89
0815ax
News 20.11.07 (engl)
NEW YORK, Nov. 20, 2007 (PRIME NEWSWIRE) -- The following is being issued by Genesis Pharmaceuticals Enterprises, Inc. (OTCBB:GTEC):
Dear Shareholders:
We are very pleased to have successfully completed the merger of Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("Laiyang Jiangbo") with Genesis Technology Group, Ltd. -- resulting in a new public company called Genesis Pharmaceuticals Enterprises, Inc. I want to take a moment to reach out to all of our shareholders in order to review where we are, how we got here and what shareholders may expect in the future.
I am pleased to report that the final terms of the merger were completed on October 1, 2007. As a result of the merger, Genesis Pharmaceuticals Enterprises, Inc. is listed on the OTC Bulletin Board and trades under the symbol "GTEC."
The new company is a pharmaceutical company whose primary operations are those of our operating subsidiary Laiyang Jiangbo. Founded in 2003, Laiyang Jiangbo focuses on the research, development, production, marketing and sales of new and sophisticated pharmaceutical products in the People's Republic of China. We have rapidly established ourselves as a leader in drug development and modern marketing in China, and our lead drugs enjoy significant market share in their categories.
Our company has a very strong financial profile
For its fiscal year ended June 30, 2007, Laiyang Jiangbo reported revenue of US$76.2 million, up by 55% over the prior year. Gross profit increased by 64% to US$55 million, and our operating income increased by 53% to US$18.3 million, over the same period. For fiscal 2007, we reported audited net income of US$22.1 million, inclusive of a one-time US$9.9 million credit for a corporate and VAT tax exemption we received from the Chinese government. Our fiscal condition is also very solid, with total assets of US$55.4 million, shareholders' equity of US$27.3 million, and cash on hand of US$17.7 million, as of June 30, 2007.
Our company is well positioned in the very attractive China pharmaceutical market
Pharmaceutical demand in China is forecast to expand by more than 13% annually to reach about US$51 billion by 2010. Strong economic growth, changing demographic patterns, and the reform and expansion of health care systems are expected to drive greater demand for drugs. Genesis Pharmaceuticals is well positioned to meet that increased demand.
Our current products are approved by the Chinese State Food and Drug Administration and include Clarithromycin sustained-release tablets, Itopride Hydrochloride granules, Ciprofloxacin Hydrochloride tablets and Paracetamol tablets. We started sales of Baobaole chewable tablets this month, in November.
We have a strong and growing pipeline of Class 1 drugs
A research and marketing driven organization, our company is driven to bring new drugs to market that can significantly improve clinical outcomes for patients in major disease categories. Since 2005, our three major drugs (Ciprofloxacin Hydrochloride, Paracetamol and Clarithromycin) have been on the approved list for reimbursement by the national healthcare Insurance Catalogue. A fourth drug (Itopride Hydochloride) is expected to get provincial government approval soon, which will make it available to over 166 million potential users. We aim to have all of our new drugs under development be on government approval lists. This is very important to maximize the availability of drugs to patients and revenue generating potential of our products.
Genesis recently announced a US$5 million private placement financing for the acquisition of a new Chinese Class 1 drug Ligustrazine Ferulic Acid Acetate ("LFAA"), a cardiac cerebral vascular drug that is designed to help reduce blood clotting and prevent platelets in the blood from clumping together. Assuming that LFAA receives all of the necessary Chinese regulatory approvals, the Company plans to put the drug into trial production in fiscal year 2008, and expects fiscal year 2009 sales of US$9.9 million and fiscal year 2010 sales of US$26.3 million.
We are adding new drugs to our product line to increase overall growth for the company. We are currently seeking government approvals to produce Felodipine Sustained Release Tablets, Radix Isatidis Dispersible Tablets, Yuandu Hanbi Capsulesa and Bezoar Yijin Tablets. Drug sales have a lifecycle during which competition often leads to decreasing profit margins over time. Our focus going forward is on Chinese Class 1 drugs that often have high profit margins. Manufacturing these sophisticated new drugs requires advanced technology, which means competitors face high barriers to entry. We are committed to having and using the latest technology to manufacture new sophisticated drugs with high profit margins.
Genesis Pharmaceuticals Enterprises, Inc. will continue to grow by expanding its distribution network of 440 full time and 620 part time representatives throughout China. Sales to end users such as doctors and hospitals, and not just distributors, help build brand recognition and customer loyalty. Sales representatives will continue to sell existing and new products to existing and new customers.
Our team is committed to operate at world class standards.
We have a strong management team in place, which has recently been enhanced by the addition of a qualified Chief Financial Officer with U.S. GAAP experience, Elsa Sung. Most of Genesis Pharmaceuticals' senior management has extensive industry experience and has been in place since the founding of Laiyang Jiangbo in 2003. They will ensure that Genesis Pharmaceuticals executes its growth strategy.
Now, after completing our going public transaction, we are committed to developing the human resources and systems required to meet our responsibilities as a U.S. public company. We are committed to high quality disclosure and shareholders will be able to observe management activities and obtain accurate information about the Company through the company's website (http://www.genesis-china.net/), which will soon be relaunched in both English and Chinese.
We are committed to the highest level of corporate governance. Our new Board of Directors consists of high level managers and independent Directors:
Cao Wubo Chief Executive Officer and Chairman of the Board
Xu Haibo Vice President, Chief Operating Officer and Director
Feng Xiaowei Outside Director
Huang Lei Outside Director
Ge Jian Outside Director
Zhang Yihua Outside Director
Rodrigo Arboleda Outside Director (From Genesis Technology Group)
Robert Cain Outside Director (From Genesis Technology Group)
Over the next several quarters we plan to take the steps required to move Genesis Pharmaceuticals to a major stock market in the U.S. so as to attain greater visibility with investors and the media and enhance the marketability of our stock.
Genesis Pharmaceuticals' senior management plans to take a trip to the U.S. in December 2007. This trip will give U.S. shareholders a chance to meet with management and ask management questions about Genesis Pharmaceuticals.
I hope that this letter has given our new shareholders some sense of the development of our company and our strategic direction. Our team looks forward to updating you on our progress through regular conference calls and visits to meet with our investors. In closing, I would like to thank our customers, shareholders, directors and employees for the Company's present and future success. Thanks to all of you for your continuing interest in Genesis Pharmaceuticals.
Cao Wubo, Chief Executive Officer and Chairman of the Board
Genesis Pharmaceuticals Enterprises, Inc.
CONTACT: Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung CFO
+1-877-895-3650, Ext. 701
info@Genesis-China.net
CCG Elite Investor Relations, Inc.
Mr. Crocker Coulson, President
+1-646-213-1915 (New York)
crocker.coulson@ccgir.com
Source: PrimeNewswire (November 20, 2007 - 12:50 PM EST)
Dear Shareholders:
We are very pleased to have successfully completed the merger of Laiyang Jiangbo Pharmaceuticals Co., Ltd. ("Laiyang Jiangbo") with Genesis Technology Group, Ltd. -- resulting in a new public company called Genesis Pharmaceuticals Enterprises, Inc. I want to take a moment to reach out to all of our shareholders in order to review where we are, how we got here and what shareholders may expect in the future.
I am pleased to report that the final terms of the merger were completed on October 1, 2007. As a result of the merger, Genesis Pharmaceuticals Enterprises, Inc. is listed on the OTC Bulletin Board and trades under the symbol "GTEC."
The new company is a pharmaceutical company whose primary operations are those of our operating subsidiary Laiyang Jiangbo. Founded in 2003, Laiyang Jiangbo focuses on the research, development, production, marketing and sales of new and sophisticated pharmaceutical products in the People's Republic of China. We have rapidly established ourselves as a leader in drug development and modern marketing in China, and our lead drugs enjoy significant market share in their categories.
Our company has a very strong financial profile
For its fiscal year ended June 30, 2007, Laiyang Jiangbo reported revenue of US$76.2 million, up by 55% over the prior year. Gross profit increased by 64% to US$55 million, and our operating income increased by 53% to US$18.3 million, over the same period. For fiscal 2007, we reported audited net income of US$22.1 million, inclusive of a one-time US$9.9 million credit for a corporate and VAT tax exemption we received from the Chinese government. Our fiscal condition is also very solid, with total assets of US$55.4 million, shareholders' equity of US$27.3 million, and cash on hand of US$17.7 million, as of June 30, 2007.
Our company is well positioned in the very attractive China pharmaceutical market
Pharmaceutical demand in China is forecast to expand by more than 13% annually to reach about US$51 billion by 2010. Strong economic growth, changing demographic patterns, and the reform and expansion of health care systems are expected to drive greater demand for drugs. Genesis Pharmaceuticals is well positioned to meet that increased demand.
Our current products are approved by the Chinese State Food and Drug Administration and include Clarithromycin sustained-release tablets, Itopride Hydrochloride granules, Ciprofloxacin Hydrochloride tablets and Paracetamol tablets. We started sales of Baobaole chewable tablets this month, in November.
We have a strong and growing pipeline of Class 1 drugs
A research and marketing driven organization, our company is driven to bring new drugs to market that can significantly improve clinical outcomes for patients in major disease categories. Since 2005, our three major drugs (Ciprofloxacin Hydrochloride, Paracetamol and Clarithromycin) have been on the approved list for reimbursement by the national healthcare Insurance Catalogue. A fourth drug (Itopride Hydochloride) is expected to get provincial government approval soon, which will make it available to over 166 million potential users. We aim to have all of our new drugs under development be on government approval lists. This is very important to maximize the availability of drugs to patients and revenue generating potential of our products.
Genesis recently announced a US$5 million private placement financing for the acquisition of a new Chinese Class 1 drug Ligustrazine Ferulic Acid Acetate ("LFAA"), a cardiac cerebral vascular drug that is designed to help reduce blood clotting and prevent platelets in the blood from clumping together. Assuming that LFAA receives all of the necessary Chinese regulatory approvals, the Company plans to put the drug into trial production in fiscal year 2008, and expects fiscal year 2009 sales of US$9.9 million and fiscal year 2010 sales of US$26.3 million.
We are adding new drugs to our product line to increase overall growth for the company. We are currently seeking government approvals to produce Felodipine Sustained Release Tablets, Radix Isatidis Dispersible Tablets, Yuandu Hanbi Capsulesa and Bezoar Yijin Tablets. Drug sales have a lifecycle during which competition often leads to decreasing profit margins over time. Our focus going forward is on Chinese Class 1 drugs that often have high profit margins. Manufacturing these sophisticated new drugs requires advanced technology, which means competitors face high barriers to entry. We are committed to having and using the latest technology to manufacture new sophisticated drugs with high profit margins.
Genesis Pharmaceuticals Enterprises, Inc. will continue to grow by expanding its distribution network of 440 full time and 620 part time representatives throughout China. Sales to end users such as doctors and hospitals, and not just distributors, help build brand recognition and customer loyalty. Sales representatives will continue to sell existing and new products to existing and new customers.
Our team is committed to operate at world class standards.
We have a strong management team in place, which has recently been enhanced by the addition of a qualified Chief Financial Officer with U.S. GAAP experience, Elsa Sung. Most of Genesis Pharmaceuticals' senior management has extensive industry experience and has been in place since the founding of Laiyang Jiangbo in 2003. They will ensure that Genesis Pharmaceuticals executes its growth strategy.
Now, after completing our going public transaction, we are committed to developing the human resources and systems required to meet our responsibilities as a U.S. public company. We are committed to high quality disclosure and shareholders will be able to observe management activities and obtain accurate information about the Company through the company's website (http://www.genesis-china.net/), which will soon be relaunched in both English and Chinese.
We are committed to the highest level of corporate governance. Our new Board of Directors consists of high level managers and independent Directors:
Cao Wubo Chief Executive Officer and Chairman of the Board
Xu Haibo Vice President, Chief Operating Officer and Director
Feng Xiaowei Outside Director
Huang Lei Outside Director
Ge Jian Outside Director
Zhang Yihua Outside Director
Rodrigo Arboleda Outside Director (From Genesis Technology Group)
Robert Cain Outside Director (From Genesis Technology Group)
Over the next several quarters we plan to take the steps required to move Genesis Pharmaceuticals to a major stock market in the U.S. so as to attain greater visibility with investors and the media and enhance the marketability of our stock.
Genesis Pharmaceuticals' senior management plans to take a trip to the U.S. in December 2007. This trip will give U.S. shareholders a chance to meet with management and ask management questions about Genesis Pharmaceuticals.
I hope that this letter has given our new shareholders some sense of the development of our company and our strategic direction. Our team looks forward to updating you on our progress through regular conference calls and visits to meet with our investors. In closing, I would like to thank our customers, shareholders, directors and employees for the Company's present and future success. Thanks to all of you for your continuing interest in Genesis Pharmaceuticals.
Cao Wubo, Chief Executive Officer and Chairman of the Board
Genesis Pharmaceuticals Enterprises, Inc.
CONTACT: Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung CFO
+1-877-895-3650, Ext. 701
info@Genesis-China.net
CCG Elite Investor Relations, Inc.
Mr. Crocker Coulson, President
+1-646-213-1915 (New York)
crocker.coulson@ccgir.com
Source: PrimeNewswire (November 20, 2007 - 12:50 PM EST)
21.11.07 16:07
#91
0815ax
News 21.11.07 (engl)
http://www.finanznachrichten.de/ext/goto.asp?id=9523905
Genesis Pharmaceuticals Announces Cooperation Agreement with The Institute of Microbiology, Chinese Academy of Sciences
LAIYANG, China, Nov. 21, 2007 (PRIME NEWSWIRE) -- Genesis Pharmaceuticals Enterprises, Inc. (OTCBB:GTEC) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it signed a cooperation agreement with The Institute of Microbiology, Chinese Academy of Sciences (IMCAS), a research institution in China that performs a wide spectrum of basic and applied research in the field of microbiology.
According to the cooperation agreement, Genesis and IMCAS will build a "Genesis Pharmaceuticals Industrialization Model" to do joint research with the goal of commercializing pharmaceutical discoveries. This Industrialization Model is IMCAS' first cooperative arrangement with a pharmaceuticals manufacturing company.
Genesis will fund the Industrialization Model's daily operations and research and development activities. Once new drugs have completed a first stage of experiments in the Industrialization Model, they will be delivered to Genesis's factory for further testing to determine the viability of commercial wide-scale production. Genesis' research and development staff will work with researchers from IMCAS to resolve issues that arise during the process of designing the manufacturing process for new drugs. Genesis will have the first right to purchase patents for any products developed by the Industrialization Model and IMCAS.
"We are very pleased that IMCAS chose Genesis to be its partner in the commercialization of new drug discoveries," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises, Inc. "Because IMCAS is the national leading research institution in the field of microbiology, we believe collaboration will bring valuable research and develop expertise to Genesis and strengthen our own R&D force. This will extend our company's use of cutting edge technologies as well as solidify our leading position in the Chinese pharmaceutical market."
About IMCAS
The Institute of Microbiology, Chinese Academy of Sciences (IMCAS) was founded on December 3, 1958. It is a national comprehensive research institution that performs a wide spectrum of basic and applied research in the field of microbiology. IMCAS hosts 300 faculty and staff, including 5 CAS academicians. Currently, it has three key laboratories: State Key Laboratory of Microbial Resources, State Key Laboratory of Plant Genomics, and CAS Key Laboratory of Systematic Mycology and Lichenology as well as nine research centers which carry out studies on microbial resources, microbial genomics, agricultural biotechnology, bio-energy and industrial biotechnology, environmental biotechnology, extremophiles, microbial metabolic engineering, molecular virology, and molecular immunology, As the national leading research and development organization in China, IMCAS successfully developed SARS vaccine.
As the national leading research institution in the field of microbiology, the IMCAS is committed to the advancement of science and technology. During the last 40 years, it has attained a number of developmental achievements in molecular evolution, pathogenicity, and cross-species propagation, as well as antiviral fields which can be the initial force for industrialization process.
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal-based medical drugs. The Company maintains a representative office in the U.S. For more information, refer to http://www.Genesis-China.net
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
CONTACT: Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung, CFO
877-895-3650, Ext. 701
info@Genesis-China.net
CCG Elite Investor Relations, Inc.
Mr. Crocker Coulson, President
+1-646-213-1915 (New York)
crocker.coulson@ccgir.com
Genesis Pharmaceuticals Announces Cooperation Agreement with The Institute of Microbiology, Chinese Academy of Sciences
LAIYANG, China, Nov. 21, 2007 (PRIME NEWSWIRE) -- Genesis Pharmaceuticals Enterprises, Inc. (OTCBB:GTEC) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it signed a cooperation agreement with The Institute of Microbiology, Chinese Academy of Sciences (IMCAS), a research institution in China that performs a wide spectrum of basic and applied research in the field of microbiology.
According to the cooperation agreement, Genesis and IMCAS will build a "Genesis Pharmaceuticals Industrialization Model" to do joint research with the goal of commercializing pharmaceutical discoveries. This Industrialization Model is IMCAS' first cooperative arrangement with a pharmaceuticals manufacturing company.
Genesis will fund the Industrialization Model's daily operations and research and development activities. Once new drugs have completed a first stage of experiments in the Industrialization Model, they will be delivered to Genesis's factory for further testing to determine the viability of commercial wide-scale production. Genesis' research and development staff will work with researchers from IMCAS to resolve issues that arise during the process of designing the manufacturing process for new drugs. Genesis will have the first right to purchase patents for any products developed by the Industrialization Model and IMCAS.
"We are very pleased that IMCAS chose Genesis to be its partner in the commercialization of new drug discoveries," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises, Inc. "Because IMCAS is the national leading research institution in the field of microbiology, we believe collaboration will bring valuable research and develop expertise to Genesis and strengthen our own R&D force. This will extend our company's use of cutting edge technologies as well as solidify our leading position in the Chinese pharmaceutical market."
About IMCAS
The Institute of Microbiology, Chinese Academy of Sciences (IMCAS) was founded on December 3, 1958. It is a national comprehensive research institution that performs a wide spectrum of basic and applied research in the field of microbiology. IMCAS hosts 300 faculty and staff, including 5 CAS academicians. Currently, it has three key laboratories: State Key Laboratory of Microbial Resources, State Key Laboratory of Plant Genomics, and CAS Key Laboratory of Systematic Mycology and Lichenology as well as nine research centers which carry out studies on microbial resources, microbial genomics, agricultural biotechnology, bio-energy and industrial biotechnology, environmental biotechnology, extremophiles, microbial metabolic engineering, molecular virology, and molecular immunology, As the national leading research and development organization in China, IMCAS successfully developed SARS vaccine.
As the national leading research institution in the field of microbiology, the IMCAS is committed to the advancement of science and technology. During the last 40 years, it has attained a number of developmental achievements in molecular evolution, pathogenicity, and cross-species propagation, as well as antiviral fields which can be the initial force for industrialization process.
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal-based medical drugs. The Company maintains a representative office in the U.S. For more information, refer to http://www.Genesis-China.net
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
CONTACT: Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung, CFO
877-895-3650, Ext. 701
info@Genesis-China.net
CCG Elite Investor Relations, Inc.
Mr. Crocker Coulson, President
+1-646-213-1915 (New York)
crocker.coulson@ccgir.com
30.11.07 18:10
#93
0815ax
Nachtrag: News 26.11.07 (engl.)
http://www.finanznachrichten.de/ext/goto.asp?id=9546003
Genesis Pharmaceuticals in agreement with Chinese Academy of Sciences
Updated: 2007-11-26 Source:Biospectrum Bureau
Genesis Pharmaceuticals Enterprises, Inc., a US pharmaceutical company with its principal operations in the People's Republic of China, today announced that it signed a cooperation agreement with The Institute of Microbiology, Chinese Academy of Sciences (IMCAS), a research institution in China that performs a wide spectrum of basic and applied research in the field of microbiology.
According to the cooperation agreement, Genesis and IMCAS will build a "Genesis Pharmaceuticals Industrialization Model" to do joint research with the goal of commercializing pharmaceutical discoveries. This Industrialization Model is IMCAS' first cooperative arrangement with a pharmaceuticals manufacturing company.
Genesis will fund the Industrialization Model's daily operations and research and development activities. Once new drugs have completed a first stage of experiments in the Industrialization Model, they will be delivered to Genesis's factory for further testing to determine the viability of commercial wide-scale production. Genesis' research and development staff will work with researchers from IMCAS to resolve issues that arise during the process of designing the manufacturing process for new drugs. Genesis will have the first right to purchase patents for any products developed by the Industrialization Model and IMCAS.
"Because IMCAS is the national leading research institution in the field of microbiology, we believe collaboration will bring valuable research and develop expertise to Genesis and strengthen our own R&D force. This will extend our company's use of cutting edge technologies as well as solidify our leading position in the Chinese pharmaceutical market," said Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals in agreement with Chinese Academy of Sciences
Updated: 2007-11-26 Source:Biospectrum Bureau
Genesis Pharmaceuticals Enterprises, Inc., a US pharmaceutical company with its principal operations in the People's Republic of China, today announced that it signed a cooperation agreement with The Institute of Microbiology, Chinese Academy of Sciences (IMCAS), a research institution in China that performs a wide spectrum of basic and applied research in the field of microbiology.
According to the cooperation agreement, Genesis and IMCAS will build a "Genesis Pharmaceuticals Industrialization Model" to do joint research with the goal of commercializing pharmaceutical discoveries. This Industrialization Model is IMCAS' first cooperative arrangement with a pharmaceuticals manufacturing company.
Genesis will fund the Industrialization Model's daily operations and research and development activities. Once new drugs have completed a first stage of experiments in the Industrialization Model, they will be delivered to Genesis's factory for further testing to determine the viability of commercial wide-scale production. Genesis' research and development staff will work with researchers from IMCAS to resolve issues that arise during the process of designing the manufacturing process for new drugs. Genesis will have the first right to purchase patents for any products developed by the Industrialization Model and IMCAS.
"Because IMCAS is the national leading research institution in the field of microbiology, we believe collaboration will bring valuable research and develop expertise to Genesis and strengthen our own R&D force. This will extend our company's use of cutting edge technologies as well as solidify our leading position in the Chinese pharmaceutical market," said Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises, Inc.
01.12.07 14:03
#94
0815ax
wäre nett, wenn jemand Ergebnisse der Konferenz
erfährt, diese hier einstellt (mit LINKS)...
http://www.rothcp.com/main/Page.aspx?PageID=7201
Presented by ROTH Capital Partners
November 29-30, 2007
The Royal Palms Resort, Phoenix, AZ
This two day conference will feature presentations from management teams of more than 30 leading Chinese companies listed here in the US. This event is another chapter in ROTH's growing commitment to China.
ROTH China - Phoenix Conference:
American Lorain Corp. (ALRC)
Asia Automotive Acquisition Corp. (AAAC)
Chardan South China Acquisition Corp (CSCA)
China Agritech Inc (CAGC)
China BAK Battery, Inc. (CBAK)
China Biotics, Inc. (CHBT)
China Direct (CDS)
China Display Technologies (LCNIA)
China Education Alliance, Inc. (CEUA)
China Fire and Security Group Inc. (CFSG)
China Gengsheng Minerals, Inc. (CHGS)
China Pharma Holdings (CPHI)
China Public Security Technology, Inc. (CPBY)
China Ritar Power Corp (CRTP)
China Security & Surveillance Tech. Inc. (CSR)
China Solar & Clean Energy Solutions, Inc. (CSOL)
China TransInfo Technology Corp. (CTFO)
Chinacast Education Corporation (CAST)
City Telecom Limited (CTEL)
Far East Energy Corp. (FEEC)
Fushi International Inc. (FSIN)
Genesis Pharmaceutical Enterprises, Inc. (GTEC)
Gulf Resources, Inc. (GUFR)
Harbin Electric Inc. (HRBN)
HLS Systems International, Ltd (HLSYF)
Huiheng Medical Inc. (HHGM)
Jaguar Acquisition Corporation (JGAC)
Jingwei International Ltd (JNGW)
Origin Agritech Limited (SEED)
ShengdaTech (SDTH)
Shengtai Pharmaceuticals (SGTI)
Sino Gas Intl Holdings (SGAS)
Sinoenergy Corporation (SNEN)
Solar Power, Inc. (SOPW)
Sutor Technology Group (SUOT)
Wonder Auto Tech Inc. (WATG)
Yucheng Technologies (YTEC)
Zhongpin Inc. (ZHNP)
http://www.rothcp.com/main/Page.aspx?PageID=7201
Presented by ROTH Capital Partners
November 29-30, 2007
The Royal Palms Resort, Phoenix, AZ
This two day conference will feature presentations from management teams of more than 30 leading Chinese companies listed here in the US. This event is another chapter in ROTH's growing commitment to China.
ROTH China - Phoenix Conference:
American Lorain Corp. (ALRC)
Asia Automotive Acquisition Corp. (AAAC)
Chardan South China Acquisition Corp (CSCA)
China Agritech Inc (CAGC)
China BAK Battery, Inc. (CBAK)
China Biotics, Inc. (CHBT)
China Direct (CDS)
China Display Technologies (LCNIA)
China Education Alliance, Inc. (CEUA)
China Fire and Security Group Inc. (CFSG)
China Gengsheng Minerals, Inc. (CHGS)
China Pharma Holdings (CPHI)
China Public Security Technology, Inc. (CPBY)
China Ritar Power Corp (CRTP)
China Security & Surveillance Tech. Inc. (CSR)
China Solar & Clean Energy Solutions, Inc. (CSOL)
China TransInfo Technology Corp. (CTFO)
Chinacast Education Corporation (CAST)
City Telecom Limited (CTEL)
Far East Energy Corp. (FEEC)
Fushi International Inc. (FSIN)
Genesis Pharmaceutical Enterprises, Inc. (GTEC)
Gulf Resources, Inc. (GUFR)
Harbin Electric Inc. (HRBN)
HLS Systems International, Ltd (HLSYF)
Huiheng Medical Inc. (HHGM)
Jaguar Acquisition Corporation (JGAC)
Jingwei International Ltd (JNGW)
Origin Agritech Limited (SEED)
ShengdaTech (SDTH)
Shengtai Pharmaceuticals (SGTI)
Sino Gas Intl Holdings (SGAS)
Sinoenergy Corporation (SNEN)
Solar Power, Inc. (SOPW)
Sutor Technology Group (SUOT)
Wonder Auto Tech Inc. (WATG)
Yucheng Technologies (YTEC)
Zhongpin Inc. (ZHNP)
05.12.07 18:06
#95
0815ax
Meldung bzgl. der China-Konferenz - zur Info
[allgemein - ohne namentlichen Bezug zu GTEC]
http://www.rothcp.com/files/ocbj120307.pdf
http://www.rothcp.com/files/ocbj120307.pdf
06.12.07 15:49
#96
0815ax
PowerPoint - Firmenpräsentation
http://www.fracturedmedia.com/gtec.ppt
22.12.07 13:41
#97
_bbb_
NEWS !
Source: Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Launched Sales of Baobaole Chewable Tablets
LAIYANG, China, Dec. 21, 2007 (PRIME NEWSWIRE) -- Genesis Pharmaceuticals Enterprises, Inc. (OTCBB:GTEC) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, today announced that it had launched its newest product Baobaole chewable tablets for sale throughout China.
Baobaole chewable tablets are a traditional Chinese medicine used to treat gastric and general abdomen discomfort. This drug stimulates appetites and promotes digestion with mild and lasting effects. It is a new, non-prescription over-the-counter (OTC) drug. A nationwide marketing campaign for Baobaole chewable tablets was started in August 2007 that included regularly shown television advertisements on the CCTV Economic Channel and Movie Channel. The Company's sales force will distribute the drug.
"We are optimistic about the launch of this product into the rapidly growing Chinese OTC market. This is our first large scale operation in the over-the-counter drug market as well as the non-prescription medicine market. We hope that this product introduction will strengthen Genesis' overall market presence and increase our market share of domestic drug sales," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises, Inc. "We anticipate that sales of Baobaole chewable tablets will have a significant impact on Company FY2008 revenues."
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceutical Enterprises, Inc. is engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis produces tablets, capsules, and granules for both western and Chinese herbal-based medical drugs. The Company maintains a representative office in the U.S. For more information, refer to http://www.Genesis-China.net. Information on the Company's website, or any other website, is not a part of this press release.
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
CONTACT: Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung, CFO
(877) 895-3650 ext. 701
genesispharm@gmail.com
CCG Elite Investor Relations, Inc.
Mr. Crocker Coulson, President
+1-646-213-1915 (New York)
crocker.coulson@ccgir.com
Genesis Pharmaceuticals Launched Sales of Baobaole Chewable Tablets
LAIYANG, China, Dec. 21, 2007 (PRIME NEWSWIRE) -- Genesis Pharmaceuticals Enterprises, Inc. (OTCBB:GTEC) ("Genesis" or the "Company"), a leading pharmaceutical company in the People's Republic of China, today announced that it had launched its newest product Baobaole chewable tablets for sale throughout China.
Baobaole chewable tablets are a traditional Chinese medicine used to treat gastric and general abdomen discomfort. This drug stimulates appetites and promotes digestion with mild and lasting effects. It is a new, non-prescription over-the-counter (OTC) drug. A nationwide marketing campaign for Baobaole chewable tablets was started in August 2007 that included regularly shown television advertisements on the CCTV Economic Channel and Movie Channel. The Company's sales force will distribute the drug.
"We are optimistic about the launch of this product into the rapidly growing Chinese OTC market. This is our first large scale operation in the over-the-counter drug market as well as the non-prescription medicine market. We hope that this product introduction will strengthen Genesis' overall market presence and increase our market share of domestic drug sales," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises, Inc. "We anticipate that sales of Baobaole chewable tablets will have a significant impact on Company FY2008 revenues."
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceutical Enterprises, Inc. is engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis produces tablets, capsules, and granules for both western and Chinese herbal-based medical drugs. The Company maintains a representative office in the U.S. For more information, refer to http://www.Genesis-China.net. Information on the Company's website, or any other website, is not a part of this press release.
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
CONTACT: Genesis Pharmaceuticals Enterprises, Inc.
Ms. Elsa Sung, CFO
(877) 895-3650 ext. 701
genesispharm@gmail.com
CCG Elite Investor Relations, Inc.
Mr. Crocker Coulson, President
+1-646-213-1915 (New York)
crocker.coulson@ccgir.com
09.01.08 17:34
#99
0815ax
Homepage aktualisiert (facelifting...)
http://www.genesis-china.net/index.asp
10.01.08 18:59
#100
0815ax
der Quartalsbericht (Juli-Sept) ist überfällig! Am
28.12.07 erschien folgende Notiz....
http://www.sec.gov/Archives/edgar/data/1091164/...07-001498-index.htm
...max. 15 Kalender-Tage später soll/muss der Bericht erscheinen - was spätestens den 12.01.08 ergeben würde.
Also - Zahlen stehen unmittelbar bevor!!
ax
http://www.sec.gov/Archives/edgar/data/1091164/...07-001498-index.htm
...max. 15 Kalender-Tage später soll/muss der Bericht erscheinen - was spätestens den 12.01.08 ergeben würde.
Also - Zahlen stehen unmittelbar bevor!!
ax